Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives
- 1.4k Downloads
Fibrous dysplasia (FD) is an uncommon and debilitating skeletal disorder resulting in fractures, deformity, functional impairment, and pain. It arises from post-zygotic somatic activating mutations in GNAS, in the cAMP-regulating transcript α-subunit, Gsα. Constitutive Gs signaling results in activation of adenylyl cyclase and dysregulated cAMP production. In the skeleton, this leads to the development of FD lesions with abnormal bone matrix, trabeculae, and collagen, produced by undifferentiated mesenchymal cells. FD may occur in isolation or in combination with extraskeletal manifestations, including hyperfunctioning endocrinopathies and café-au-lait macules, termed McCune-Albright syndrome (MAS). This review summarizes current clinical and translational perspectives in FD/MAS, with an emphasis on FD pathogenesis, natural history, pre-clinical and clinical investigation, and future directions.
KeywordsFibrous dysplasia McCune-Albright syndrome GNAS gene Gsα FGF23
Compliance with Ethical Standards
Conflict of Interest
Cemre Robinson, Michael T Collins, and Alison M Boyce declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human subjects performed by any of the authors.
With regard to the authors’ research cited in this paper, all institutional and national guidelines for the care and use of laboratory animals were followed.
This research was supported by the Intramural Research Program of the National Institute of Dental and Craniofacial Research
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Riminucci M. et al. Fibrous dysplasia as a stem cell disease. J Bone Miner Res, 2006. 21 Suppl 2: p. P125-31.Google Scholar
- 13.Collins MT, Riminucci M, Bianco P. Fibrous dysplasia. In: Rosen C, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Washington, DC: American Society of Bone and Mineral Research: p. 2013: 786–793.Google Scholar
- 18.•Boyce AM, Collins MT. Fibrous Dysplasia/McCune-Albright Syndrome. In GeneReviews(R), Pagon RA, et al, Editors. 1993, University of Washington, Seattle: Seattle WA. This review contains specific diagnostic and treatment algorithms compiled from the highest quality evidenced-based literature and expert opinion currently available.Google Scholar
- 19.••Amit M et al. Surgery versus watchful waiting in patients with craniofacial fibrous dysplasia—a meta-analysis. PLoS One. 2011;6(9):e25179. This meta-analysis establishes that prophylactic optic nerve decompression is contraindicated in patients with FD involving the optic canals without evidence of objective vision loss.Google Scholar
- 26.••Boyce AM et al. Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess. J Clin Endocrinol Metab. 2013;98(1):E126–34. This paper demonstrates that early diagnosis and treatment of growth hormone excess in FD/MAS prevents long-term craniofacial morbidity.Google Scholar
- 40.••Leet AI et al. Bone-grafting in polyostotic fibrous dysplasia. J Bone Joint Surg Am. 2016;98(3):211–9. This study demonstrates that the common surgical practice of bone grafting is frequently ineffective in patients with FD, particularly children.Google Scholar
- 44.Lee J, Fitzgibbon E, Chen Y, Kim H, Lustig L, Akintoye S, Collins M, Kaban L. Clinical guidelines for the management of craniofacial fibrous dysplasia. 2012. 24 Suppl 1:S2(7): p. Suppl 1:S2.Google Scholar
- 46.•Boyce AM et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab. 2014;99(11):4133–40. This study reports the first randomized controlled trial in FD, demonstrating that oral alendronate is ineffective in improving FD-related pain or the radiographic appearance of FD lesions.Google Scholar
- 51.Salenave S. et al. Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab, 2014: p. jc20133826.Google Scholar
- 62.Prolia [package insert]. Thousand Oaks, CA., 2010. Amgen, Inc.Google Scholar
- 63.Xgeva [package insert]. Thousand Oaks, CA., 2010. Amgen, Inc.Google Scholar